AEON Biopharma (AEON)
XASE:AEON
Want to see AEON full AI Analyst Report?
Top Page
AEON Biopharma
(NYSE MKT:AEON)
Select Model
Select Model
Rating:42Neutral
Price Target:
$0.82
▼(-25.36% Downside)
Action:Reiterated
Date:05/19/26
The score is primarily driven down by weak financial performance (no revenue, recurring losses, cash burn, and negative equity), which also heightens financing/dilution risk. Technicals are also unfavorable with price below key moving averages and negative MACD. Corporate events add further risk due to NYSE American noncompliance/delisting concerns, while valuation provides limited support given a negative P/E and no dividend yield.
Positive Factors
Focused clinical-stage pipeline
AEON’s strategy centers on a single, well-defined botulinum toxin program (ABP-450) targeting neurological indications. A focused pipeline concentrates R&D resources, clarifies regulatory pathways and partnership potential, and makes milestone delivery and clinical readouts a durable driver of value over months.
Negative Factors
No revenue; recurring large losses
AEON remains pre-revenue and posted roughly $60M in TTM losses, leaving operations wholly dependent on external funding. Persistent negative earnings erode balance-sheet resilience and force repeated financing decisions, a structural constraint that elevates execution and dilution risk over the coming months.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused clinical-stage pipeline
AEON’s strategy centers on a single, well-defined botulinum toxin program (ABP-450) targeting neurological indications. A focused pipeline concentrates R&D resources, clarifies regulatory pathways and partnership potential, and makes milestone delivery and clinical readouts a durable driver of value over months.
Read all positive factors
AEON Biopharma (AEON) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$22.49M
Dividend YieldN/A
Average Volume (3M)273.24K
Price to Earnings (P/E)―
Beta (1Y)0.97
Revenue GrowthN/A
EPS Growth-101.45%
CountryUS
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-5.03
Shares Outstanding26,307,210
10 Day Avg. Volume605,674
30 Day Avg. Volume273,237
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.20
Price to Sales (P/S)0.00
P/FCF Ratio-0.63
Enterprise Value/Market Cap0.29
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-346.86
Enterprise Value/Ebitda-0.36
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.96
Revenue Forecast (FY)$16.30M
AEON Biopharma Business Overview & Revenue Model
Company Description
AEON Biopharma, Inc., a biopharmaceutical company, focuses on the development botulinum toxins for the treatment of debilitating medical conditions. It also develops 900 kDabotulinum toxin complex, ABP-450, for migraine, cervical dystonia, and gas...
How the Company Makes Money
null...
AEON Biopharma Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
6
Very Negative
Cash Flow
12
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -19.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -18.21M | -16.22M | -27.73M | -52.74M | -48.36M | -36.88M |
| Net Income | -60.11M | -39.22M | 42.01M | -384.63M | -52.56M | -55.64M |
Balance Sheet | ||||||
| Total Assets | 8.63M | 5.56M | 3.14M | 6.84M | 10.78M | 6.44M |
| Cash, Cash Equivalents and Short-Term Investments | 6.24M | 3.01M | 13.00K | 5.16M | 9.75M | 5.13M |
| Total Debt | 2.63M | 35.74M | 12.96M | 278.00K | 131.53M | 86.89M |
| Total Liabilities | 25.38M | 60.59M | 31.71M | 159.89M | 281.19M | 230.26M |
| Stockholders Equity | -16.75M | -55.03M | -28.57M | -153.04M | -287.50M | -234.94M |
Cash Flow | ||||||
| Free Cash Flow | -12.04M | -17.31M | -20.29M | -47.83M | -35.89M | -28.60M |
| Operating Cash Flow | -12.04M | -17.31M | -20.29M | -47.83M | -35.58M | -28.43M |
| Investing Cash Flow | 0.00 | -4.00K | 0.00 | 0.00 | -306.00K | -170.00K |
| Financing Cash Flow | 7.83M | 20.30M | 15.15M | 14.00M | 40.51M | 13.56M |
AEON Biopharma Technical Analysis
Negative
1.10
Price Trends
0.98
Negative
1.05
Negative
0.95
Negative
Market Momentum
-0.05
Positive
44.79
Neutral
43.64
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AEON, the sentiment is Negative. The current price of 1.1 is above the 20-day moving average (MA) of 0.92, above the 50-day MA of 0.98, and above the 200-day MA of 0.95, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 44.79 is Neutral, neither overbought nor oversold. The STOCH value of 43.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AEON.
AEON Biopharma Risk Analysis
AEON Biopharma disclosed 61 risk factors in its most recent earnings report. AEON Biopharma reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
AEON Biopharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $5.86M | ― | -684.86% | ― | ― | 95.40% | |
47 Neutral | $9.50M | -0.87 | -341.23% | ― | ― | 71.83% | |
46 Neutral | $6.98M | -2.11 | -9.02% | ― | ― | -1979.68% | |
42 Neutral | $22.49M | -0.85 | 0.02% | ― | ― | -101.45% | |
| ― | $6.14M | -5.65 | ― | ― | ― | ― |
* Healthcare Sector Average
AEON
AEON Biopharma
0.86
0.37
74.49%
IMNN
Imunon
2.13
-3.08
-59.09%
XTLB
XTL Biopharmaceuticals Sponsored ADR
2.53
-1.67
-39.76%
APM
Aptorum Group
0.84
-0.06
-6.67%
RNAZ
TransCode Therapeutics
6.18
-1.76
-22.20%
AEON Biopharma Corporate Events
Business Operations and StrategyRegulatory Filings and Compliance
AEON Biopharma Releases Updated Investor Relations Presentation
Neutral
May 14, 2026
On May 14, 2026, AEON Biopharma, Inc. made a new corporate presentation available in the investor relations section of its website, which management may also use in future meetings with investors and other stakeholders. The company emphasized that...
Delistings and Listing ChangesRegulatory Filings and Compliance
AEON Biopharma Receives Additional NYSE American Noncompliance Notice
Negative
Apr 3, 2026
On March 31, 2026, AEON Biopharma received an additional notice from NYSE American that it is not in compliance with Section 1003(a)(ii), which requires at least $4 million in stockholders’ equity when a company has losses in three of its fo...
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and Compliance
AEON Biopharma Strengthens Finance Leadership with New CFO
Positive
Mar 9, 2026
On March 6, 2026, AEON Biopharma’s board appointed veteran biotech executive John Bencich as chief financial officer effective March 9, 2026, and principal financial officer effective April 1, 2026, aligning its finance leadership with its p...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.